Enriched Autologous Fat Grafting for Treating Pain at Amputation Sites (AMP-5)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by University of Pittsburgh
Sponsor:
Collaborator:
Information provided by (Responsible Party):
J. Peter Rubin, MD, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT01645722
First received: March 21, 2012
Last updated: March 19, 2014
Last verified: March 2014
  Purpose

The objective of this pilot study is to assess the efficacy of minimally invasive autologous fat transfers at the amputation sites and the modulation of pain at the respective sites. Our investigators hypothesize that autologous fat grafting can provide a minimally invasive therapy to effectively mitigate pain syndromes at amputation sites, by introducing volume stable subcutaneous tissue over bony prominences and peripheral nerve trunks, thereby avoiding major surgical revisions and preserving limb length. The investigators further hypothesize that enriching the fat graft with autologous adipose stromal cells, a regenerative medicine approach, will lead to improved retention of the fat graft over time and result in a more favorable outcome.

The Investigators will evaluate:

  1. Treatment of painful amputation sites in 5 patients with fat grafting, intended to provide additional subcutaneous tissue padding over bony structures and nerve trunks. Limb anatomy and healing of the graft over time, along with stability/persistence of the new tissue, will be assessed by high resolution CT scanning with 3D reconstruction. Patients will be followed for 24 months after treatment to define long term outcomes. Patients will be enrolled who have pain at an amputation site that limits function and/or interferes with the ability to use a prosthesis.
  2. Biologic properties of the cells within the fat graft and correlate with clinical outcomes. This will include adipose stem cell yield per volume of fat tissue, cell proliferation, capacity for adipogenic differentiation, lipolysis, and cell sub-population analysis by multiparameter flow cytometry. Results of these assays will be correlated with graft volume retention to search for predictors of good clinical outcome that are related to variation on adipose biology between subjects.
  3. Quality of life measurements in patients before and after autologous fat grafting using validated psychosocial measures. This will include SF 36, the Beck inventory, and instruments designed for assessing limb function.

Condition Intervention
Amputation Stumps
Pain
Procedure: Procedure/Surgery: Enriched Fat grafting

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Enriched Autologous Fat Grafting for Treating Pain at Amputation Sites

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • Treatment of Painful Amputation Sites [ Time Frame: 26 months ] [ Designated as safety issue: No ]
    1) Treat painful amputation sites in 5 patients with fat grafting, to provide additional subcutaneous tissue padding over bony structures and nerve trunks. Limb anatomy and healing of the graft over time, along with stability/persistence of the new tissue, will be assessed by high resolution CT scanning with 3D reconstruction. Patients will be followed for 24 months after treatment to define long term outcomes. Patients will be enrolled who have pain at an amputation site that limits function and/or interferes with the ability to use a prosthesis.


Secondary Outcome Measures:
  • Assessment of biological cell properties within fat graft [ Time Frame: 20 years ] [ Designated as safety issue: No ]
    Assess biologic properties of cells within the fat graft and correlate with clinical outcomes to include adipose stem cell yield per volume of fat tissue, cell proliferation, capacity for adipogenic differentiation, lipolysis, and cell sub-population analysis by multiparameter flow cytometry. Assay results to be correlated with graft volume retention to search for predictors of good clinical outcome that are related to variation on adipose biology between subjects. Banked cells are stored for current assay or assay developed at a FUTURE date for correlation.

  • Quality of Life improvement [ Time Frame: 26 months ] [ Designated as safety issue: No ]
    Measure quality of life in patients before and after autologous fat grafting using validated psychosocial measures. This will include SF 36, the Beck inventory, and instruments designed for assessing limb function.


Estimated Enrollment: 5
Study Start Date: July 2012
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Procedure/Surgery: Enriched Fat grafting
Enriched Fat grafting
Procedure: Procedure/Surgery: Enriched Fat grafting
Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then injected into the amputation stump.In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
Other Names:
  • Fat Grafts
  • Autogenous Fat Transfers (AFT)
  • Wounded warriors
  • Amputation site pain
  • Amputation pain

  Hide Detailed Description

Detailed Description:

Traumatic amputations are prevalent and pose many challenges for our wounded warriors. A recent publication reported that during the current conflicts, over 950 military personnel have sustained combat-related amputations, with 15% of them occurring more than 12 weeks after initial injury (1). Updated statistics place this number of amputees at over 1050 (personal communication, COL Paul Pasquina, Chief of the Integrated Department of Orthopaedics and Rehabilitation, Walter Reed National Military Medical Center-WRNMMC). The ability of a wounded warrior to gain optimal function after an amputation most often depends on his or her ability to successfully fit and adapt to a prosthesis. Once out of the acute phase, many patients with amputations suffer from pain when wearing a prosthesis, either from thin soft tissue cover over bony structures or peripheral nerves not well padded with soft tissue. Extrinsic residual limb pain is usually mechanical in origin related to the prosthetic socket or other prosthetic components. It is often the result of a mismatch between residual limb tissue tolerance and the prosthetic loads on the soft tissues. This sensitivity is often accentuated by superficial nerve trunks or neuromas at severed nerves that are exposed to excessive external mechanical loading (2). Poor socket interface, secondary skin breakdown, and/or pain may severely limit function.

This presents a very difficult clinical problem and historically, when possible, the clinical procedure would be to involve the surgical revision of the amputation site with associated shortening of the bone, lengthy scars, and prolonged healing. If a below the knee amputation has to be converted to an above knee level, then there are serious functional implications. For local tissues at the amputation site that are of poor quality (e.g. scarred or covered with a skin graft), a distant muscle flap may be required (3,4). These flaps may require transfer to the amputation site using microvascular anastomosis of the blood vessels. The procedure is highly invasive and can add the morbidity of decreased function, deformity, and risk of wound healing problems at the muscle donor site. Failure rates in lower limb flaps can be as high as 18.5% (5, 6). Flap ulceration rates tend to be higher in these weight-bearing flaps, both skin and muscle free flaps frequently need secondary debulking procedures to improve function, and painful neuromas are not uncommon (6,7).

A clinical solution that allows for the minimally invasive generation of new soft tissue padding at an amputation site without the need for further limb shortening, lengthy scars, a prolonged recovery, and significant donor site morbidity would have the potential to significantly help our wounded warriors and change clinical practice.

Autologous fat grafting as a potential solution. Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 5mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the donor site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure. It has the advantages of:

  • Minimal access incisions
  • Ability to transfer significant amounts of tissue (hundreds of grams of tissue)
  • Can be used in setting of previous surgical procedures and presence of hardware
  • Usually performed as outpatient procedure
  • Minimal donor site morbidity at graft harvest site
  • Low risk compared with more invasive surgical procedures
  • Can be repeated multiple times, if necessary, even using the same donor sites

The transfer of autologous tissues is not a new concept but just another method as we have seen with many types of flaps using various combinations of muscle, fat and skin have been well documented. Tissue flaps come from many different locations, and are used in many different ways to accomplish the desired results. Flaps have their own blood supply, they are more resilient than skin grafts, and usually produce much better results from a cosmetic standpoint because they can provide a better match for skin tone and texture. Skin flaps are also a better choice when tissue "bulk" is needed to fill contour defects. The obvious advantage is to use autologus tissue versus xenografts and allografts; each having known risks of rejection and adverse events.

The literature has unequivocally demonstrated that clinical fat grafting in buttocks (a similar weight-bearing anatomic region) can be performed safely and effectively with retention rates approximating 75% up to 2 years and beyond (23-25). In an OVID database search of fat grafting articles, over 9000 articles have referenced the use of fat grafts in a wide arena of clinical situations. Specifically to this application over 100 references were relevant to this proposal and provided below.(26-132)

The investigators propose a clinical trial to assess the efficacy of minimally invasive autologous fat transfer for addressing pain and poor prosthetic fit at amputation sites. This surgical procedure involves the immediate transplantation of a subject's own tissue and does not require FDA oversight. Importantly, we will use our knowledge and expertise working with adipose stromal cells to compare a regenerative medicine cell therapy modification of the fat grafting procedure with more traditional fat graft preparations.

The biggest problem associated with fat grafting is unpredictable rates of fat graft resorption. This is likely related to the ability of the regenerating adipose tissue to rapidly develop a new blood supply. In this study, we will test a regenerative medicine approach of enriching the adipose graft with autologous adipose stem cells (stromal cell enriched adipose grafting). This may serve to improve graft retention over time and potentially improve functional outcomes.

A modified preparation of the fat graft involves concentrating the endogenous stromal cells in the graft material in an effort to increase graft retention over time. The aspirated fat material used for fat grafting consists of mature adipocytes, a small amount of fibrous tissue, and immature adipose stromal cells (ASCs). These adipose stromal cells are a mixed population of non-lipid laden cells that serve to turn over mature adipocytes and vascular elements. "Preadipocytes," as well as endothelial precursor cells and multilineage progenitor cells, are found. Of note, ASCs have been shown to stimulate angiogenesis when stressed under hypoxic conditions and these cells may be instrumental in healing and volume retention of fat grafts. Yoshimura, et. al. (133) found that fat aspirated with a liposuction cannula (i.e. the method of fat harvest for fat grafting) is deficient in ASCs compared to whole fat. This is due to the fact that a major portion of ASCs are located around larger blood vessels that are left intact in the donor site after liposuction with a blunt cannula. The relative lack of ASCs in lipoaspirate may explain problems with fat graft reabsorption over time. Enriching lipoaspirate with ASCs should increase angiogenesis and, therefore, fat graft retention. This cell therapy approach takes advantage of the innate ability of ASC's to both secrete angiogenic factors and also differentiate into mature adipocytes. The improved blood vessel ingrowth can result in improved graft volume retention and superior reconstructive outcomes.

Our group at the University of Pittsburgh has developed clinically useful and scalable GMP methods for ASC extraction under an NIH funded program, led by Dr. Rubin (Co-Director of the Adipose Stem Cell Center) in collaboration with Dr. Albert Donnenberg, director of the clinical laboratories for cell processing. We are currently starting a fully funded project with the Armed Forces of Regenerative Medicine (AFIRM). We are utilizing our extraction techniques to perform ASC enriched fat grafting for facial trauma reconstruction and this has received IRB approval at our institution. This process is regulated under human cells, tissues and cellular and tissue-based products (HCT/P) guidelines under section 361 of the CFR (21CFR1271.10). HCT/P therapies are exempt from the requirement for the submission of an Investigational New Drug (IND) application.

For this project proposal, we have expanded the team to encompass expertise in reconstructive fat grafting, lower extremity reconstruction, physical medicine and rehabilitation, prosthetic design, nutritional support, and evaluation of psychosocial outcomes. Given the initial success with autologous fat grafting for facial reconstruction after trauma (analysis ongoing), even without enrichment of the graft with adipose stromal cells, we believe this therapy can be effectively applied for the treatment of limb pain. This procedure can be performed on an outpatient basis with no significant incisions on the limb, only small port sites measuring less than 5 mm. It is noted that this is a completely new, experimental application of a conventional treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Aged 18 years or older and able to provide informed consent
  2. Have suffered injury resulting in an amputation with pain that limits the fitting and use of a prosthesis, despite maximal attempts to refit the prosthesis and/or change the design of the prosthesis
  3. Be at least 3 months post-injury or post-surgery (from trauma procedures) so that acute edema is resolved
  4. Soft tissue deficiencies are noted at amputation stump and are covered by intact skin
  5. Willing and able to comply with follow up examinations, including radiographic studies
  6. Active military
  7. Able to provide informed consent

Exclusion Criteria:

  1. Age less than 18 years
  2. Patient has inability to provide informed consent process.
  3. Amputated limb area intended for treatment has open wounds, tunneling or drainage with active infection unresolved with one course of antibiotic treatment.
  4. Active infection anywhere in the body
  5. Diagnosed with cancer within the last 12 months and /or presently receiving chemotherapy or radiation treatment
  6. Known coagulopathy symptoms /diagnosis
  7. Systemic disease that would render the fat harvest and injection procedure, along with associated anesthesia, unsafe to the patient.
  8. Pregnancy
  9. History of Diabetes Mellitus
  10. History of severe peripheral arterial disease
  11. Diagnosis of Schizophrenia or Bipolar Disorder (Subjects who are found to be stable on medication and receive psychiatric clearance could be eligible for study participation per the Physician's discretion).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01645722

Contacts
Contact: Carroll Lee, BSN 412-864-2587 mockjl@upmc.edu

Locations
United States, Pennsylvania
University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Carroll Lee, BSN    412-864-2587    mockjl@upmc.edu   
Principal Investigator: J.Peter Rubin, MD         
Sub-Investigator: Sydney Coleman, MD         
Sub-Investigator: Kacey G Marra, PhD         
Sub-Investigator: Gretchen Haas, PhD         
Sub-Investigator: Jeffrey Gusenoff, MD         
Sub-Investigator: Diana Mermon, MS         
Sub-Investigator: Albert Donnenberg, PhD         
Sub-Investigator: Vera S Donnenberg, PhD         
Sub-Investigator: Rory Cooper, PhD         
Sub-Investigator: Sara Peterson, MBA, CPO         
Sub-Investigator: Patsy Simon, RN, BS         
Sub-Investigator: Annmarie Kelleher, MS, OT, CCRC         
Sub-Investigator: Ian Valerio, MD         
Sub-Investigator: Jenelle Mock, BSN         
Sub-Investigator: Wendy Wakefield, CRNP         
Sub-Investigator: Elizabeth Radomsky, PhD         
Sub-Investigator: Jacqueline Bliley, BS         
Sub-Investigator: Ryan Mitchell, MD         
Sub-Investigator: Mara Yerk, BS         
Sub-Investigator: Caroll Lee, BSN         
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: J.Peter Rubin, MD University of Pittsburgh
  More Information

Publications:

Responsible Party: J. Peter Rubin, MD, Principal Investigator, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT01645722     History of Changes
Other Study ID Numbers: PRO11090215
Study First Received: March 21, 2012
Last Updated: March 19, 2014
Health Authority: United States: Institutional Review Board
United States: Federal Government

Keywords provided by University of Pittsburgh:
Fat Grafts
Autogenous Fat Transfers (AFT)
Wounded warriors
Amputation pain

ClinicalTrials.gov processed this record on October 20, 2014